Meeting NewsVideo

VIDEO: J&J lowers Lipiflow activator price to improve access to technology

NEW ORLEANS – Joseph Boorady, OD, FAAO, vice president of ocular surface for Johnson & Johnson Vision, announced a price cut on the activators for its Lipiflow device.

“Our hope is that this lower activator cost makes the Lipiflow MGD [meibomian gland dysfunction] treatment more accessible and lays the foundation for changing the standard of care for MGD,” he said.

Boorady also shared positive clinical study results for the technology.

NEW ORLEANS – Joseph Boorady, OD, FAAO, vice president of ocular surface for Johnson & Johnson Vision, announced a price cut on the activators for its Lipiflow device.

“Our hope is that this lower activator cost makes the Lipiflow MGD [meibomian gland dysfunction] treatment more accessible and lays the foundation for changing the standard of care for MGD,” he said.

Boorady also shared positive clinical study results for the technology.

    See more from SECO